Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.51 |
| ▸ | MYC | P01106 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17737082 | 0.90 | KDM4E (0.71) | KDM4EUSP2ENPP2POLBKMT2A | |
| SCHEMBL23610369 | 0.90 | KDM4E (0.71) | KDM4EUSP2ENPP2POLBKMT2A | |
| SCHEMBL12306047 | 0.85 | KDM4E (0.57) | KDM4EUSP2ENPP2POLBKMT2A | |
| SCHEMBL14802425 | 0.85 | GFER (0.67) | KDM4EUSP2KMT2AMEN1MYC | |
| SCHEMBL3028108 | 0.85 | MAPT (0.69) | KDM4EPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL5226625 | 0.85 | LMNA (0.51) | USP2POLBKMT2AMEN1SLC6A7 | |
| SCHEMBL13506522 | 0.84 | USP2 (0.64) | KDM4EUSP2ENPP2KMT2AMEN1 | |
| SCHEMBL20193318 | 0.84 | KDM4E (0.65) | KDM4EUSP2ENPP2POLBKMT2A | |
| SCHEMBL3466014 | 0.82 | TDP1 (0.64) | KDM4EUSP2ALDH1A1MAPTLMNA | |
| SCHEMBL27515415 | 0.82 | CA12 (0.64) | KDM4EUSP2POLBALDH1A1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4395549-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | Oerth Bio LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023034411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | OERTH BIO LLC (US) | 2023-03-09 | — | — | WO | disclosed |
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-01 | — | — | US | disclosed |
| US-9724418-B2 | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-08 | — | — | US | disclosed |
| EP-2296659-B1 | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-21 | — | — | EP | disclosed |
| US-20150320741-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-12 | — | — | US | disclosed |
| US-9107946-B2 | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-18 | — | — | US | disclosed |
| US-8865720-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-21 | — | — | US | disclosed |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-06 | — | — | US | disclosed |
| US-8557825-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-7704998-B2 | anticancer agents; catalytic hydrogenation | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-27 | — | — | US | disclosed |
| WO-2009147170-A2 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-10 | — | — | WO | disclosed |
| EP-1485365-B1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-14 | — | — | EP | disclosed |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | VAN EMELEN KRISTOF | 2008-05-08 | — | — | US | disclosed |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF V | 2007-06-21 | — | — | US | disclosed |
| US-7205304-B2 | medicine to inhibit proliferative conditions, such as cancer and psoriasis | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| US-20050113373-A1 | medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-26 | — | — | US | disclosed |
| EP-1485365-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076422-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| WO-1996019475-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320741-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | PPARG, PPARA, DGAT1 | KDM4E 3115/4885USP2 3999/4885ENPP2 684/4885 |
| US-20050113373-A1 | medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample | HDAC1, HDAC11, HDAC4 | KDM4E 112/4885USP2 1933/4885ENPP2 1373/4885 |
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | PPARG, PPARA, DGAT1 | KDM4E 3115/4885USP2 3999/4885ENPP2 684/4885 |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | KDM4E 58/4885USP2 1355/4885ENPP2 2522/4885 |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | KDM4E 58/4885USP2 1355/4885ENPP2 2522/4885 |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | HDAC1, HDAC11, HDAC3 | KDM4E 296/4885USP2 1394/4885ENPP2 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.